GlassScriptPhysician profile
Behzad Kalaghchi
NPI 1356337158
$5,393.06
in general payments reported to CMS, 2019-2025
31 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $329 · 2021: $596 · 2022: $886 · 2023: $1,295 · 2024: $883 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276 · Education: $47.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.60 |
| Education | $47.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.28 | 2019-2025 | |
| Boston Scientific Corporation | $841.42 | 2019-2023 | |
| Janssen Biotech, INC. | $495.65 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $494.34 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $362.40 | 2019-2024 | |
| Celgene Corporation | $334.34 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.87 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $160.49 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $142.62 | 2022-2025 | |
| Genzyme Corporation | $140.53 | 2022-2025 | |
| Braintree Laboratories, INC. | $126.11 | 2025 | Suflave, Sutab |
| Qol Medical, LLC | $103.94 | 2022-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $100.73 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $94.27 | 2023-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $73.64 | 2023-2025 | Yuflyma, Vegzelma, Zymfentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $73.08 | 2023 | |
| Olympus America INC. | $55.83 | 2019-2023 | Endoclot Phs, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn), Disposable Grasping Forceps |
| Intercept Pharmaceuticals, INC. | $54.85 | 2023-2025 | Ocaliva |
| Lilly USA, LLC | $44.75 | 2025 | Omvoh |
| Ambu INC. | $35.90 | 2020 | |
| Ferring Pharmaceuticals INC. | $33.81 | 2021-2023 | Rebyota |
| Digestive Care, INC. | $33.50 | 2025 | Pertzye |
| Vibrant Gastro, INC. | $31.10 | 2024 | Vibrant Starter Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.64 | 2023 | Cyltezo |
| Orphalan INC | $24.83 | 2025 | Cuvrior |
| Daiichi Sankyo INC. | $21.81 | 2023 | Injectafer |
| Amgen INC. | $21.37 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.53 | 2024 | Bylvay |
| Fresenius Kabi USA, LLC | $18.67 | 2023 | Idacio |
| Ardelyx, INC. | $15.67 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behzad Kalaghchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.